Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanoxel plus Herzuma in relapsed or metastatic salivary gland carcinoma
KCT0003545Phase 2Completed
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, trastuzumab in salivary gland cancer (SGC), sponsored by Samyang Biopharmaceuticals Corporation. Started Sep 2018; status: completed.
02
Drugs
paclitaxeltrastuzumab
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on KCT0003545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003545.